Objective: To explore the survival time of the patients with small cell lung cancer (SCLC) treated with postoperative chemotherapy and the factors affecting the prognosis. Methods: The clinical data of 111 patients treated with postoperative chemotherapy, 88 males and 23 females, aged 57 (32-81...
therapyoracceptprophylacticcranialirradiationorPSscore0—1havelongersurvivaltimeandtheywouldbenet frommuhi—treatmentmodalities. 【Keywords】smallcelllungcancer;radiotherapy;chemotherapy;prognesis ModemOncology2014,22(10):2315—2318 【摘要】 目的:回顾性分析我院93例广泛期SCLC放化综合治疗的疗效,对影响小细胞肺癌...
Small cell lung cancer (SCLC) is a highly aggressive tumor with a 5-year survival rate of less than 6%. A heterogenous disease, SCLC is classified into four subtypes that include tumors with neuroendocrine (NE) and non-NE features. Immune checkpoint blockade (ICB) therapy has been recently a...
Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC). “Receiving an Orphan...
在非小细胞肺癌(non-small cell lung cancer, NSCLC)患者中,PD-L1和肿瘤突变负荷(tumor mutation burden, TMB)是两种重要的生物标志物,对筛选适合免疫治疗的患者有一定作用,例如在晚期驱动基因阴性的NSCLC一线治疗中,PD-L1≥50%的患者可选择单药Pembr...
which is an earlier stage of lung cancer, and then there is extensive-stage SCLC, which is the typical metastatic SCLC. The prognosis is different for these 2 groups. If someone has limited-stage SCLC, we see a 5-year survival rate of approximately 25%. There is a subset of those patie...
小细胞肺癌(Small cell lung cancer,SCLC)约占肺癌总数的15%,是肺癌中侵袭性最强的亚型,其恶性程度高、转移早、进展迅速,总体预后不良。SCLC一般分为局限期(Limited-stage,LS)和广泛期(Extensive-stage,ES),约60%-70%的SCLC患者在确诊时已处于广泛期1。ES-SCLC在治疗初期对放化疗敏感,但有效时间持续短...
Objective To evaluate the correlation of different fractionation schedules in radiotherapy with the local control (LC) and overall survival (OS) rates in patients with extensive-stage small cell lung cancer (ES-SCLC), and to figure out the relationship between different fractionation schedules in radi...
Objective To investigate the impact of postoperative radiotherapy ( PORT) on the prognosis of earlystage smallcell lung cancer ( SCLC) . Methods The clinical data of 71 patients who were clinically diagnosed with stage T12 N0 M0 SCLC and underwent radical resection surgery in our hospital from 19...
“There is a significant need for new treatment options for small cell lung cancer, which has a 5-year survival rate of only 6% overall,” said Jonathan Cheng, MD, vice president, oncology clinical research, Merck Research Laboratories, the developer of the PD-1 inhibitor. “Keytruda has alr...